338 related articles for article (PubMed ID: 17206695)
1. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
3. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
van Staa TP; Card T; Logan RF; Leufkens HG
Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
6. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
Tang J; Sharif O; Pai C; Silverman AL
Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
[TBL] [Abstract][Full Text] [Related]
7. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
[TBL] [Abstract][Full Text] [Related]
8. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminosalicylic acid and chemoprevention: does it work?
Lopez A; Peyrin-Biroulet L
Dig Dis; 2013; 31(2):248-53. PubMed ID: 24030235
[TBL] [Abstract][Full Text] [Related]
10. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.
Munkholm P
Aliment Pharmacol Ther; 2003 Sep; 18 Suppl 2():1-5. PubMed ID: 12950413
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
12. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
13. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
Carrat F; Seksik P; Colombel JF; Peyrin-Biroulet L; Beaugerie L;
Aliment Pharmacol Ther; 2017 Feb; 45(4):533-541. PubMed ID: 27995656
[TBL] [Abstract][Full Text] [Related]
14. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
OʼConnor A; Packey CD; Akbari M; Moss AC
Inflamm Bowel Dis; 2015 Nov; 21(11):2562-9. PubMed ID: 26296062
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.
Nieminen U; Jussila A; Nordling S; Mustonen H; Färkkilä MA
Int J Cancer; 2014 Jan; 134(1):189-96. PubMed ID: 23797639
[TBL] [Abstract][Full Text] [Related]
16. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein CN; Blanchard JF; Metge C; Yogendran M
Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
[TBL] [Abstract][Full Text] [Related]
17. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Cohen HD; Das KM
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
[TBL] [Abstract][Full Text] [Related]
18. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.
Samadder NJ; Mukherjee B; Huang SC; Ahn J; Rennert HS; Greenson JK; Rennert G; Gruber SB
Cancer; 2011 Apr; 117(8):1640-8. PubMed ID: 21472711
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
20. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
